善良的亦云
Lv1
20 积分
2023-04-02 加入
-
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
15小时前
已关闭
-
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
15小时前
已关闭
-
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
15小时前
已关闭
-
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
16小时前
已关闭
-
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
16小时前
已关闭
-
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
16小时前
已完结
-
Hereditary Angioedema: A Review of the Current and Evolving Treatment Landscape
4个月前
已完结
-
Hereditary Angioedema: A Rare Cause of Acute Pancreatitis
4个月前
已完结
-
Normalization of C1 Inhibitor in a Patient with Hereditary Angioedema
4个月前
已完结
-
PLAGL2‐EGFR‐HIF‐1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity
11个月前
已完结